Ling‐Ming Tseng

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations

Medicine, Oncology, Pharmacology +16

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2016 · 874 citations

Medicine, Immunology, Oncology +17

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

José Baselga, Seock‐Ah Im, Hiroji Iwata et al. · The Lancet Oncology · 2017 · 539 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

Siyuan Zhang, Wen-Chien Huang, Ping Li et al. · Nature Medicine · 2011 · 517 citations · Full text

Medicine, Molecular Biology, Oncology +16

Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer

Yu‐Chih Chen, Yi‐Wei Chen, Han‐Shui Hsu et al. · Biochemical and Biophysical Research Communications · 2009 · 474 citations

Medicine, Molecular Biology, Oncology +16